Health equity has become a central focus in U.S. healthcare policy, as disparities in access, affordability, and outcomes continue to affect vulnerable populations. The Inflation Reduction Act (IRA) introduces sweeping changes to drug pricing and Medicare negotiations—reforms designed to lower costs, but with implications that extend far beyond economics. These changes raise important questions: How will pricing reforms impact access for underserved communities? Will value-based frameworks help close gaps in care or create new barriers?
Watch this webinar to explore how policy shifts under the IRA intersect with health equity, what challenges remain, and what strategies stakeholders are using to promote fairness in access and affordability. If you don't have time to watch the entire event, we also invite you to download the Summary eBook from the handouts tab in the webinar recording player to access the concise summary of the presentation and access important resources from our sponsors:
Identifying Disparities with Real-World Data: Structured, Unstructured, and SDOH
Michael Munsell, PhD
Director
Real World Data HEOR
Norstella
How the IRA Could Influence R&D Pipelines and Investment
Haripriya Jain, MS, MBAExecutive Director
PPD Evidera Health Economics and Market Access
Thermo Fisher Scientific
- Understand how real-world data can be used to evaluate key IRA policy provisions.
- Identify the variables available to researchers across multiple data sources, as well as their strengths and limitations, both as independent sources and linked at the patient-level.
- Propose policy-relevant research questions that can be answered with real-world data.
- The Inflation Reduction Act (IRA) may pressure manufacturer revenues, impacting R&D investments due to its price negotiations and caps.
- Manufacturers could focus on high-return projects and shift attention to biologics, as small molecules face disadvantages under IRA provisions.
- Investments in chronic conditions and post-approval R&D might decrease due to risks associated with Medicare spending and price negotiation eligibility.
- Capital may be redirected towards late-stage clinical assets, highlighting the importance of building a robust evidence base for navigating commercial uncertainties.
Presenters
Haripriya Jain
Priya Jain is a seasoned life sciences strategy consultant with over 18 years of biotech and pharmaceuticals experience, with specialization in the areas of market access and product commercialization. She is an Executive Director on the PPD™ Evidera™ Health Economics and Market Access team and is based in San Francisco, California.
Michael Munsell
Michael Munsell, PhD, is the Director of Real World Data HEOR at Norstella, specializing in study design, statistical methods, and the dissemination of real world evidence. He holds a PhD from Brandeis University, with a focus in computational economics, and an undergraduate degree in economics from the University of Michigan.
Sponsor
The PPD clinical research business of Thermo Fisher Scientific Inc.
Panalgo, LLC
Content Partners
Scientist.com
Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.
We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.
Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.
